Unilever has similar problems to those Procter & Gamble faced four years ago, and now has the same activist investor on its board. But times otherwise have moved on.
Keep Reading →
May 31 - Hedge Funds, Insider Trading - Comments
Below we present the list of the top 5 healthcare stocks the experts at Sphera Global Healthcare Fund are buying.
Keep Reading →
February 20 - Hedge Funds, News - Comments
Crispin Odey’s flagship hedge fund lost money again in 2020, deepening the gloom for the bearish manager as he tries to revive his shrinking firm and fights an indecent assault...
Keep Reading →
January 6 - Hedge Funds, Insider Trading - Comments
The extended weekend is now over, and Wall Street is once again paying attention to the U.S.
Keep Reading →
May 28 - News - Comments
Fisher Investments was founded in 1979 by billionaire Ken Fisher.
Keep Reading →
November 13 - Dividend Stocks, Hedge Funds, News - Comments
Daniel Loeb's hedge fund, Third Point, has trimmed the number of nominees it is making to the Campbell Soup board to five, sources tell CNBC.
Keep Reading →
November 9 - Hedge Funds, Insider Trading - Comments
Stan Druckenmiller is a billionaire, and was the long-time manager of Duquesne Capital. Now, he oversees a family office, but his investing strategy is mostly the same.
Keep Reading →
February 24 - Hedge Funds, News - Comments
To me, flu season is a lot like Christmas; there's a defined time period when we expect it to occur, yet it seems to appear earlier and earlier every year.
Keep Reading →
September 23 - News - Comments
According to the American Cancer Society, more than 60,000 new cases of thyroid cancer will be diagnosed in the U.S., and about 1,850 people are expected to die from the disease...
Keep Reading →
September 23 - News - Comments
It's arguably health care's biggest name.
Keep Reading →
September 19 - News - Comments
The small patient pool for medullary thyroid cancer, or MTC, isn't going to move the needle for a large pharmaceutical company. But Exelixis, Inc.
Keep Reading →
September 17 - News - Comments
Through the years, London-based drugmaker AstraZeneca plc (ADR) (NYSE:AZN) and U.S. pharmaceutical firm Merck & Co., Inc.
Keep Reading →
September 17 - News - Comments
The Chinese calendar says 2013 is the year of the snake, but the market says it's the year of biotech.
Keep Reading →
September 17 - News - Comments
GlaxoSmithKline plc (ADR) (NYSE:GSK) and its partner Theravance Inc (NASDAQ:THRX) recently scored a second victory in their quest to treat chronic obstructive pulmonary disease...
Keep Reading →
September 16 - News - Comments
AstraZeneca plc (ADR) (NYSE:AZN) may have missed out on acquiring the oncology platform of Onyx Pharmaceuticals, but it responded by pulling the trigger on a $500 million deal...
Keep Reading →
September 15 - News - Comments
There hasn't been a dull moment for investors of Theravance Inc (NASDAQ:THRX) since the company submitted an NDA for COPD/asthma drug BREO before the Food and Drug Administration...
Keep Reading →
September 12 - News - Comments
Investors hate to wake up and find that one of their stocks has opened nearly 30% lower than the prior day's close.
Keep Reading →
September 11 - News - Comments
I know it's like comparing apples and oranges, but humor me for a moment.
Keep Reading →
September 11 - News - Comments
Make that four collaborations between Biogen Idec Inc. (NASDAQ:BIIB) and ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) in the last two years.
Keep Reading →
September 10 - News - Comments
Over the past decade, the Food and Drug Administration has taken multiple steps to improve the process by which drugs are developed and eventually brought to market.
Keep Reading →
September 4 - News - Comments
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on.
Keep Reading →
September 3 - News - Comments
The phrase "PDUFA date" is thrown around frequently when discussing biotech and pharma companies.
Keep Reading →
August 27 - News - Comments
Alkermes Plc (NASDAQ:ALKS) is primarily known for its schizophrenia and multiple sclerosis drug treatments.
Keep Reading →
August 26 - News - Comments
At the end of June, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) announced that it had rejected an offer from Amgen, Inc.
Keep Reading →
August 24 - News - Comments
It's no wonder that plenty of companies are developing diabetes drugs. There are more than 370 million people with diabetes worldwide.
Keep Reading →
August 20 - News - Comments
A rising tide lifts all boats, but the opposite isn't true in the stock market. The major indexes slipped this week, while a handful of health-care stocks soared.
Keep Reading →
August 17 - News - Comments
GlaxoSmithKline plc (ADR) (NYSE:GSK) has been accused of making illegal payments to Chinese doctors and government officials by siphoning them through travel agencies.
Keep Reading →
August 12 - News - Comments
In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)'s extended phase 3 program for its inhaled insulin, Afrezza, is likely to produce ...
Keep Reading →
August 12 - News - Comments
Every month, I select one or more stocks that I'll be buying in real life for my Roth IRA.
Keep Reading →
August 12 - News - Comments
As human beings it can sometimes be difficult for us to see the good in a bad situation.
Keep Reading →
August 7 - News - Comments
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has been stuck is share purgatory for a number of years.
Keep Reading →
August 6 - News - Comments
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) announced its second-quarter financial results on Thursday prior to the market open.
Keep Reading →
August 2 - News - Comments
Keryx Biopharmaceuticals (NASDAQ:KERX) announced its second-quarter results before the market opened on Thursday.
Keep Reading →
August 1 - News - Comments
Array Biopharma Inc (NASDAQ:ARRY), a biotech company primarily focused on discovery of drugs for cancer treatment, is making forays into the asthma market.
Keep Reading →
August 1 - News - Comments
Several companies are striving hard to manage their business and retain investors by providing an attractive dividend.
Keep Reading →
July 31 - News - Comments
The good news was that the big pharmaceutical company beat earnings estimates. Merck & Co., Inc.
Keep Reading →
July 31 - News - Comments
AstraZeneca plc (ADR) (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) announced last week that they are making another attempt at U.S.
Keep Reading →
July 30 - News - Comments
Three years ago, the company told investors not to worry. It had a plan to replace the $6 billion drug that lost patent protection last year.
Keep Reading →
July 28 - News - Comments
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) added 3% to its one-month 60% gains on Monday because of continued speculation of a buyout.
Keep Reading →
July 24 - News - Comments
The healthcare sector has been one of the best sectors for dividend hunters -- most of the companies operating in the sector generate massive cash flow and payout a large chunk...
Keep Reading →
July 24 - News - Comments
Big pharma placed its bets on a new class of diabetes drugs called SGLT2. Last year, buzz surrounded late-stage projects from Johnson and Johnson (NYSE:JNJ), Eli Lilly & Co.
Keep Reading →
July 22 - News - Comments
The "people familiar with the matter" are out in full force spouting off about who's bidding for Onyx Pharmaceuticals, Inc.
Keep Reading →
July 19 - News - Comments
AstraZeneca plc (ADR) (NYSE:AZN)’s financial results have been on a downward spiral lately, as patent expirations have led to sharp declines in sales of its leading drugs.
Keep Reading →
July 15 - News - Comments
"More means less." Amarin Corporation plc (ADR) (NASDAQ:AMRN) demonstrated this seemingly contradictory maxim today following its announcement of a new public offering.
Keep Reading →
July 9 - News - Comments
A few months back, Barron's featured an intriguing pharmaceutical company that goes by the name The Medicines Company (NASDAQ:MDCO).
Keep Reading →
July 5 - News - Comments
The promising cancer developer confirmed over the weekend that Amgen had made an offer to acquire Onyx for $120 per share, a 38.2% premium above Friday's close.
Keep Reading →
July 5 - News - Comments
A few weeks ago, CAPS player Valyooo started a lively debate with a blog entry asking for opinions on stocks vs. high-yield bonds.
Keep Reading →
July 5 - News - Comments
When screening for health-care dividend stocks, it's tempting to look for the ones with the highest yield.
Keep Reading →
July 5 - News - Comments
In the last couple of years, the biotechnology industry has been on a roll.
Keep Reading →
July 2 - News - Comments
Merck & Co., Inc. (NYSE:MRK) stock has become dependent on its diabetes drug Januvia over the past couple of years for revenue growth.
Keep Reading →
July 1 - News - Comments
